Investor Presentaiton
Hematology
Reblozyl BET Inhibitor Breyanzi golcadomide Abecma
alnuctamab
GPRC5D
iber/mezi
GPRC5D CAR T has differentiated MoA/construct, addressing
unmet need in post-BCMA treated population
GPRC5D-targeted CAR construct
Anti-GPRC5D domain¹
Hinge and transmembrane domain¹
4-1BB1,2
CD3-zeta1,2
Matching modality to mechanism
TCE
CAR T
Repeated administration
One-time infusion
Critical need for new targets as the number of post-BCMA
treated patients increases³
GPRC5D is a clinically validated receptor highly expressed on
MM cells with limited expression in other tissues and shows
great potential for treatment of advanced MM1
Overexpression of GPRC5D is associated with poor
disease prognosis¹
Hypothesis:
Deliver strong anti-tumor efficacy with a better
on-target/off-tumor tolerability profile
Though CART manufacturing and scalability is bespoke,
therapy is a one-time infusion leading to significant
efficacy and a manageable tolerability profile4
1. Smith EL, et al. Science Transl Med. 2019;11:eaau7746. 2. Song D-G, et al. Cancer Res. 2011;71:4617-4627. 3. Mailankody S, et al. N Engl J Med. 2022;387:1196-1206.
Not for Product Promotional Use
87
Ill Bristol Myers Squibb 4. Bal S, et al. EHA 2023 [Presentation #S193].View entire presentation